UTHR has announced that it will continue the FREEDOM-EV study of Orenitram extended-release tablets. This is good news. However, many analysts were hoping for better news. A better news would have been if the effectiveness was so good that there would be no need to continue the study as planned.
UTHR remains a takeover target but the probability of a buyout is now lower
What To Do Now
Those in the stock may consider continuing to hold and change stops to mental stops in the zone of $98 to $108.43.